Targeted drugs for advanced thyroid cancer with a RET mutation
Part of Cancer clinical trials.
This study tests whether two targeted drugs (pralsetinib and anlotinib) can help people with a certain type of advanced thyroid cancer that has a RET gene mutation. These drugs are designed to block signals that help cancer grow. The study aims to see how well these drugs work and how safe they are.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of thyroid cancer called medullary thyroid cancer.
- Your cancer has spread or is advanced and needs treatment.
- Your cancer has a specific change called a RET gene mutation.
- You have not been treated with certain targeted drugs before.
- Your overall health is good enough to carry out daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
This trial tests a combination of two oral and infused drugs to slow or shrink advanced thyroid cancer that has stopped responding to initial treatment. It may offer a new option for people with limited choices.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Hear when a new Medullary Thyroid Cancer (MTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.